Date	Price Target	Rating	Analyst
9/4/2025		Hold → Buy	Maxim Group
8/16/2024	$4.00 → $1.50	Buy → Neutral	UBS
11/17/2023	$11.00	Outperform	Robert W. Baird
11/8/2023		Buy → Hold	Maxim Group
7/24/2023	$12.00	Buy	Citigroup
5/1/2023	$24.00	Buy	Truist
3/28/2023	$11.00	Neutral → Buy	UBS
6/14/2022	$7.00	Neutral	UBS

More analyst ratings

FDA Approval for LOQTORZI issued to COHERUS BIOSCIENCES INC

10/30/23 8:08:07 AM ET

$CHRS

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $CHRS alert in real time by email

Biologic License Application (BLA): 761240
Company: COHERUS BIOSCIENCES INC

Products on BLA 761240

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
LOQTORZI	TORIPALIMAB-TPZI	240MG/6ML(40MG/ML)	INJECTABLE;INJECTION	Prescription	None	No	No

Approval Date(s) and History, Letters, Labels, Reviews for BLA 761240

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
10/27/2023	ORIG-1	Approval		N/A; Orphan		Label is not available on this site.

Get the next $CHRS alert in real time by email

Crush Q3 2025 with the Best AI Superconnector

Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

AI-Powered Inbox

Context-aware email replies

Strategic Decision Support

Get Started with Standout.work

Recent Analyst Ratings for
$CHRS

Date	Price Target	Rating	Analyst
9/4/2025		Hold → Buy	Maxim Group
8/16/2024	$4.00 → $1.50	Buy → Neutral	UBS
11/17/2023	$11.00	Outperform	Robert W. Baird
11/8/2023		Buy → Hold	Maxim Group
7/24/2023	$12.00	Buy	Citigroup
5/1/2023	$24.00	Buy	Truist
3/28/2023	$11.00	Neutral → Buy	UBS
6/14/2022	$7.00	Neutral	UBS

More analyst ratings

Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody

– CHS-114 demonstrated robust and selective depletion of CCR8+ Tregs as well as favorable immune remodeling in tumor tissue from head and neck squamous cell carcinoma (HNSCC) patients – – CHS-114 administration resulted in selective depletion of CCR8+ Tregs and a >50% increase in intratumoral CD8 T cells – turning tumors "hot" REDWOOD CITY, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today announced new multiomic tumor and blood-based biomarker data from the dose expansion arm of its ongoing Phase 1b clinical trial evaluating CHS-114, a selective, cytolytic anti-CCR8 antibody, as monotherapy and in combination with toripalimab in patients with recurre

11/7/25 9:00:00 AM ET

$CHRS

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update

– CHS-114, a highly selective Treg depleter, clinical program expanded to include colorectal cancer – – Q3 2025 ending cash, cash equivalents and marketable securities of $191.7 million – – LOQTORZI® net revenue was $11.2 million, a 12% increase over Q2 2025 – – Conference call today at 5:00 p.m. Eastern Standard Time – REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today reported financial results for the third quarter ended September 30, 2025 and provided an overview of recent business highlights. "In Q3 2025, we gained significant momentum on our strategy to develop innovative oncology therapies that substantially increase patient sur

11/6/25 4:14:07 PM ET

$CHRS

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer

– Responsible for Corporate Development, Investor Relations, Government Affairs – REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today announced that Arvind Sood has joined the Company as Chief Strategy and Corporate Affairs Officer reporting to Denny Lanfear, Chairman and Chief Executive Officer. Mr. Sood's responsibilities include key externally facing and strategic functions. "We are thrilled to have a such a well-regarded senior biotechnology executive join us as we advance our innovative, next generation cancer therapeutics and drive LOQTORZI® revenues in nasopharyngeal carcinoma," said Denny Lanfear, Coherus Oncology Chairman and Chief

11/6/25 1:54:45 PM ET

$CHRS

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

$CHRS
Leadership Updates

Live Leadership Updates

View All

Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer

11/6/25 1:54:45 PM ET

$CHRS

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors

REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ((Coherus or the Company, NASDAQ:CHRS) today announced that Rita Karachun, CPA, CGMA, most recently Senior Vice President (SVP) and Global Controller for Merck & Co., Inc., (Merck) was appointed to its Board of Directors effective May 31, 2024. Ms. Karachun has nearly four decades of experience leading finance, accounting, and SEC reporting functions at multi-billion-dollar global companies. Her experience includes more than 17 years at Merck, where she held positions of increasing financial management responsibility. As Global Controller at Merck, Ms. Karachun managed a global team responsible for all accou

6/5/24 9:00:00 AM ET

$CHRS

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Coherus BioSciences Appoints Dr. Michael Ryan to its Board of Directors

– Recognized biopharma commercialization and market access leader to support Coherus' strategic vision and multiple product launches – REDWOOD CITY, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus" or the "Company", NASDAQ:CHRS), today announced the appointment to its Board of Directors of biopharma commercialization and market access expert Michael Ryan, Pharm. D. Dr. Ryan has four decades of experience working in academia and the biopharmaceutical industry bringing high-value therapeutics to patients. Dr. Ryan's distinguished career includes most recently serving as Senior Vice President and Head for U.S. and Worldwide Value, Access, Pricing and Health Ec

7/20/23 4:04:53 PM ET

$CHRS

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

$CHRS
Financials

Live finance-specific insights

View All

Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update

11/6/25 4:14:07 PM ET

$CHRS

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025

REDWOOD CITY, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today announced that its third quarter 2025 financial results will be released after market close on Thursday, November 6, 2025. Starting at 5:00 p.m. Eastern Time on November 6, 2025, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call. Conference Call Information When: Thursday, November 6, 2025, starting at 5:00 p.m. Eastern Standard Time To access the conference call, please pre-register thr

10/30/25 8:30:00 AM ET

$CHRS

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

– LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 – – Data readouts for CHS-114 and casdozokitug on track for 1H 2026 – – Q2 2025 ending cash, cash equivalents and marketable securities of $238 million – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today reported financial results for the second quarter ended June 30, 2025 and provided an overview of recent business highlights. "Coherus Oncology is dedicated to significantly extending survival for people with cancer," said Denny Lanfear, Coherus Chairman and Chief Executive Officer. "We are execu

8/7/25 4:41:26 PM ET

$CHRS

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

FDA Approval for LOQTORZI issued to COHERUS BIOSCIENCES INC

Products on BLA 761240

Approval Date(s) and History, Letters, Labels, Reviews for BLA 761240

Original Approvals or Tentative Approvals

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for $CHRS

FDA Approval for LOQTORZI issued to COHERUS BIOSCIENCES INC

Products on BLA 761240

Approval Date(s) and History, Letters, Labels, Reviews for BLA 761240

Original Approvals or Tentative Approvals

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for $CHRS

$CHRS Analyst Ratings

Coherus BioSciences upgraded by Maxim Group

Coherus BioSciences downgraded by UBS with a new price target

Robert W. Baird initiated coverage on Coherus BioSciences with a new price target

$CHRS Insider Trading

SEC Form 4 filed by Director O'Donnell-Tormey Jill

SEC Form 4 filed by Director Newcomer Lee Nisley

SEC Form 4 filed by Director Wahlstrom Mats

$CHRS Press Releases

Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody

Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update

Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer

$CHRS FDA approvals

FDA Approval for CIMERLI issued to COHERUS BIOSCIENCES INC